Results 61 to 70 of about 82,153 (256)

Adaptive designs and applications used in clinical trials

, 2020
Amaç: Bu çalışmanın amacı, klinik araştırmalarda uygulanan adaptif tasarımların incelenmesi, araştırılması ve kullanılmakta olan bazı adaptif tasarımlara ait uygulamaların gösterilmesidir.
Kaçar, Sedar
core  

Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study

, 2022
The topic of the therapeutic use of cannabinoids in Parkinson’s disease (PD) is broadly discussed and frequently comes up in the outpatient clinic. So far, there are only a few randomized clinical trials assessing the effects of cannabinoids in PD.
Krismer, Florian, Werner Poewe, Ellmerer, Philipp, Ritter, Marcel, Dora Valent, Valent, Dora, Marina Peball, Klaus Seppi, Philipp Ellmerer, Marini, Kathrin, Atbin Djamshidian, Djamshidian, Atbin, Marcel Ritter, Seppi, Klaus, Poewe, Werner, Florian Krismer, Peball, Marina, Heim, Beatrice, Carbone, Federico, Beatrice Heim, Federico Carbone, Kathrin Marini   +21 more
core   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review

, 2022
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However, unlike in young patients, the outcomes of elderly patients are poor, and they are under-represented in phase III trials.
Radić-Krišto, Delfa, Stefan Mrđenović, Gašparov, Slavko, Igor Aurer, Galušić, Davor, Martinović, Marko, Nika Popović, Hude, Ida, Marko Martinović, Kužat, Luka, Klara Brčić, Slavko Gašparov, Inga Mandac Smoljanović, Aurer, Igor, Delfa Radić-Krišto, Ostojić Kolonić, Slobodanka, Ida Hude, Goran Rinčić, Rinčić, Goran, Mrđenović, Stefan, Marin Međugorac, Milunović, Vibor, Divošević, Sunčana, Grubešić, Aron, Dejan Strahija, Luka Kužat, Mandac Smoljanović, Inga, Slobodanka Ostojić Kolonić, Strahija, Dejan, Popović, Nika, Davor Galušić, Sunčana Divošević, Brčić, Klara, Međugorac, Marin, Vibor Milunović, Aron Grubešić   +35 more
core   +1 more source

The role of the arginine metabolome in pain: implications for sickle cell disease

Journal of Pain Research, 2016
Nitya Bakshi,1–2 Claudia R Morris3–6 1Division of Pediatric Hematology-Oncology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; 2Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta,
Bakshi N, Morris CR
doaj  

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling. [PDF]

, 2013
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Meads et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
Meads, C., P Barton, P Guest, C Davenport, Borowiack, E., Khan, K., Thangaratinam, S, Martin-Hirsch, P., Sundar, S.; id_orcid, Zapalska, A., Guest, Peter, Thangaratinam, S.; id_orcid, Barton, P., C Meads, T Roberts, Kowalska, M., P Auguste, Małysiak, S, M Kowalska, A Zapalska, Khan, K, S Sundar, S Thangaratinam, Meads, C, Roberts, T., Davenport, C, Sundar, S, Barton, P, Auguste, P., Kowalska, M, Guest, P, P Martin-Hirsch, Martin-Hirsch, P, Davenport, C.; id_orcid, S Małysiak, Zapalska, A, Roberts, T, E Borowiack, Auguste, P, Małysiak, S., K Khan, Borowiack, E   +41 more
core   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials [PDF]

, 2019
Background: Weekly adalimumab (Humira®) is approved for the treatment of hidradenitis suppurativa (HS) based on the 12-week placebo-controlled periods of the two phase III PIONEER trials.
M.M. Okun, Geng, Z., Geng, Z. (Z.), Armstrong, A.W. (A. W.), E.P. Prens, Gulliver, WPF, Williams, D.A. (D. A.), W.P.F. Gulliver, Williams, D.A., Kimball, AB, Jemec, G.B.E. (Gregor), Armstrong, A W, Gu, Y, Mrowietz, U, U. Mrowietz, Jemec, G.B.E., Mrowietz, U. (Ulrich), S.B. Forman, Z. Geng, D.A. Williams, H.D. Teixeira, Teixeira, H.D., Gu, Y., Kimball, A.B., Okun, M.M., Jemec, GBE, Teixeira, H.D. (H. D.), Gulliver, W.P. (Wayne P.), Mrowietz, U., Armstrong, A.W., Y. Gu, A.B. Kimball, G.B.E. Jemec, Williams, DA, Gu, Y. (Yihua), Kimball, A.B. (Alexa), Okun, M. (Martin), Forman, S.B. (S. B.), Prens, E.P., Teixeira, HD, A.W. Armstrong, Okun, M M, Prens, Errol, Gulliver, W.P.F., Forman, S B, Prens, E.P. (Errol), Forman, S.B., Geng, Z   +47 more
core   +1 more source